Thalamic deep brain stimulation in traumatic brain injury: a phase 1, randomized feasibility study.

TitleThalamic deep brain stimulation in traumatic brain injury: a phase 1, randomized feasibility study.
Publication TypeJournal Article
Year of Publication2023
AuthorsSchiff ND, Giacino JT, Butson CR, Choi EYoung, Baker JL, O'Sullivan KP, Janson AP, Bergin M, Bronte-Stewart HM, Chua J, DeGeorge L, Dikmen S, Fogarty A, Gerber LM, Krel M, Maldonado J, Radovan M, Shah SA, Su J, Temkin N, Tourdias T, Victor JD, Waters A, Kolakowsky-Hayner SA, Fins JJ, Machado AG, Rutt BK, Henderson JM
JournalNat Med
Volume29
Issue12
Pagination3162-3174
Date Published2023 Dec
ISSN1546-170X
KeywordsBrain Injuries, Traumatic, Deep Brain Stimulation, Feasibility Studies, Humans, Quality of Life, Thalamus
Abstract

Converging evidence indicates that impairments in executive function and information-processing speed limit quality of life and social reentry after moderate-to-severe traumatic brain injury (msTBI). These deficits reflect dysfunction of frontostriatal networks for which the central lateral (CL) nucleus of the thalamus is a critical node. The primary objective of this feasibility study was to test the safety and efficacy of deep brain stimulation within the CL and the associated medial dorsal tegmental (CL/DTTm) tract.Six participants with msTBI, who were between 3 and 18 years post-injury, underwent surgery with electrode placement guided by imaging and subject-specific biophysical modeling to predict activation of the CL/DTTm tract. The primary efficacy measure was improvement in executive control indexed by processing speed on part B of the trail-making test.All six participants were safely implanted. Five participants completed the study and one was withdrawn for protocol non-compliance. Processing speed on part B of the trail-making test improved 15% to 52% from baseline, exceeding the 10% benchmark for improvement in all five cases.CL/DTTm deep brain stimulation can be safely applied and may improve executive control in patients with msTBI who are in the chronic phase of recovery.ClinicalTrials.gov identifier: NCT02881151 .

DOI10.1038/s41591-023-02638-4
Alternate JournalNat Med
PubMed ID38049620
PubMed Central ID8126422
Grant ListR01 NS111019 / NS / NINDS NIH HHS / United States
UH3 NS095554 / NS / NINDS NIH HHS / United States
Related Institute: 
Brain Health Imaging Institute (BHII)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065